Navigation Links
BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Date:5/8/2008

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter ended March 31, 2008. The Company reported revenues of $10.8M in the first quarter of 2008, compared to $9.2M in the first quarter of 2007. The net loss for the quarter ended March 31, 2008 was $13.1M, or $0.34 per share, compared to a net loss for the quarter ended March 31, 2007 of $8.8M, or $0.30 per share.

Research and development (R&D) expenses were $21.9M in the first quarter of 2008, compared to R&D expenses of $16.2M in the first quarter of 2007. The increase is primarily attributable to costs associated with the advancement of clinical programs, the costs related to manufacturing lead drug candidates and the increase in personnel related costs, which included an increase in the non-cash share-based compensation charge.

General and administrative (G&A) expenses for the first quarter of 2008 were $2.9M compared to G&A expenses of $2.4M for the same quarter in 2007. The higher G&A expenses were primarily due to an increase in professional fees and personnel related costs.

As of March 31, 2008, the Company had cash, cash equivalents and investments of $81.2 million.

"Our financial flexibility and stability will allow us to pursue all of the significant milestones we have set forth for our pipeline candidates," said Jon P. Stonehouse, Chief Executive Officer of BioCryst. "2008 will be a very active year in the clinic for BioCryst, and we are fortunate to have the financial basis to advance our drug candidates in order to deliver the greatest value to both patients and our shareholders."

Recent Corporate Highlights

Forodesine HCl cutaneous T-cell lymp
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
2. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
3. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
4. BioCryst to Present at UBS 2007 Global Life Sciences Conference
5. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
6. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
7. Dendreon Reports First Quarter 2008 Financial Results
8. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
9. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
10. Oncothyreon Reports First Quarter 2008 Financial Results
11. iCAD Reports First Quarter 2008 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ire/--Reportlinker.comannouncesthatanewmarketresea...ioethanolMarketAnalysisandForecaststo2013 ,, ...anol-Market-Analysis-and-Forecasts-to-2013.html ,...013 ,, Summary ,, Thereportprovidesdetaile...dtheBrazilbioethanolmarketinparticular.Italsohelps...
(Date:11/24/2009)...n German . , Whether it,s CD packaging, con...Frequency Identification) are increasingly finding...le to label objects or goods and identify them aut...nner can read and process the data contained in th...r production conditions of up to 100 degrees Celsi...
(Date:11/24/2009)...ssador to also Visit Detroit , ... Appia, French Ambassador for International Invest... Agency, , , , ,What: Ambassador Appia is availab...ss initiatives adopted by France to further develo... innovation and development., , ,When: Available f...
(Date:11/24/2009)...4/PRNewswire/--Twomoreprestigiousuniversitieshavej...ardandcareerssiteforlifescienceprofessionals. ,...thejobboard,joining28othermajorlifesciencetraining...er.com ,isonlyforpost-graduatesinthelifesciences.W...nternet,BioCareerCenteristheonlyonethatserveslifes...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Intelligence inside metal components 2Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2
...care Policy, SAN CARLOS, Calif., April 8, 2008 T...) have approved at-home sleep testing,for obstruct...d that,suspected sleep apnea sufferers undergo fac... continuous positive airway pressure (CPAP) treatm...attended home monitoring devices.,This decision wi...
...iotechnologies, Inc. (MBI) is pleased to announce ... at the Biodiversity Institute of Ontario,Universi...n MBI,s early,access program for the Apollo 100 ST...automated and integrated system for DNA sample pre...BI,s MOV(TM),(Microscale-On-Chip-Valve) technology...
...utics, Inc., a,privately held ophthalmic-focused b...entation of data from two Phase 3 clinical trials ... 0.05%, a topical steroid in,the treatment of post...ven,in a presentation by Michael Korenfeld, MD dur...e Surgery Annual Symposium in Chicago, Illinois., ...
Other Biology Technology:Medicare Approves in Home Sleep Apnea Testing 2Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing 2Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium 2Sirion Therapeutics Highlights Pivotal Trial Results of Durezol(TM) at the American Society of Cataract and Refractive Surgery Annual Symposium 3
(Date:11/23/2009)...NNATINew research presents strong evidence that th...oth outdoor traffic-related pollution and indoor e... one or the other exposure alone. , Environmen...ati (UC) College of Medicine have shown that child... particles and indoor endotoxin during early life ...
(Date:11/23/2009)...E, Calif. -- More than 160 participants gathered t... Keck FUTURES INITIATIVE conference. This year,s t...ists, engineers, and medical researchers to explor...urrounding the emerging field of synthetic biology...ology at Princeton University and this year,s conf...
(Date:11/23/2009)...ON, WI, November 16, 2009 -- A USDOE and USDA stud..., idle cropland, and cropland pasture could be con...nnial grasses, such as switchgrass, from which bio...tock. Economically viable production of a perennia...ies of biomass are removed annually is expected to...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Synthetic biology offers new opportunities for interdisciplinary collaboration 2Switchgrass produces biomass efficiently 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 1Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Onco 14899 4Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 1Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 2Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 3Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 4Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 5Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 6Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 7Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 8Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 9Shamir Optical Industry Ltd Reports Third Quarter 2009 Results 6374 10instaCare Corp Continues Turnaround Reports 58 25 Revenues Increase for First Three Quarters 6370 1instaCare Corp Continues Turnaround Reports 58 25 Revenues Increase for First Three Quarters 6370 2
... Dr. Francois Bolduc keeps more than 300,000 fruit...tes their genes and then tests their mental abilit...ike a comic book villain, but Bolduc is no mad sci...erta,s Faculty of Medicine & Dentistry, Bolduc has... called FMR1 in a fruit fly,s brain will wipe out ...
... Increasing pressures from climate change will rea...g a significant decline in the health of the plane...s in an international report issued today. , Rel...and the International Coral Reef Initiative, inter... "Status of Coral Reefs of the World: 2008" provid...
... This release is available in French . , Mont...an stunt growth and foster weight gain during pube...urnal of Clinical Endocrinology & Metabolism . Eve...m the McGill University Health Centre (MUHC) and t...ir study, vitamin D deficiency was found to cause ...
Other Biology News:'Fly guy' makes memory breakthrough 2Time running out on coral reefs as climate change becomes increasing threat 2Time running out on coral reefs as climate change becomes increasing threat 3Lack of vitamin D causes weight gain and stunts growth in girls 2
Bsu36 I from Promega
Multiskan EX from Thermo Scientific
Mouse Anti-Ubiquitin, Multi Monoclonal Antibody, Unconjugated, Clone FK2 from Assay Designs/Stressgen Bioreagents
T4 DNA Polymerase from Invitrogen
Biology Products: